Original articleThe Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular Age-Related Macular Degeneration
Section snippets
Methods
This retrospective cohort study design was approved by the Western Institutional Review Board (Olympia, Washington, USA). It complied with the Health Insurance Portability and Accountability Act of 1996 and followed the tenets of the Declaration of Helsinki.
Results
A total of 374 patients with treatment-naïve neovascular AMD in at least 1 eye treated with anti-VEGF therapy were identified. Among these 374 patients, 232 patients (266 eyes) met the eligibility criteria. The mean age was 86.3 ± 8.1 years; 67.7% of eyes (180/266) were from female patients and 95.5% (254/266) from white patients, followed by 2.6% (7/266) Hispanic, 1.5% (4/266) Asian, and 0.4% (1/266) African-American.
Using the FA classification system, the distribution of neovascular subtypes
Discussion
The identification of neovascular AMD lesion subtypes and their relative frequencies in newly diagnosed eyes have been assessed by FA alone with the occasional addition of indocyanine green angiography (ICG).23, 24, 25, 26, 27, 28, 29, 30 To our knowledge, the present study is the first to determine lesion frequencies using both an FA-based and an anatomic classification using both FA and OCT.
The anatomic classification of NV is accomplished by using both FA and OCT to define the location of
Jesse J. Jung received his BA in biology and psychology at Washington University in St. Louis and his MD at Emory University School of Medicine. After completing a transitional year internship at Emory University School of Medicine, he completed his Ophthalmology residency and was Chief Resident during his final year of residency at New York University School of Medicine/Manhattan Eye, Ear, and Throat Hospital. He is currently a second year vitreoretinal fellow at the Edward S. Harkness Eye
References (58)
- et al.
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Ophthalmology
(2012) - et al.
Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration
Ophthalmology
(2000) - et al.
Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes
Am J Ophthalmol
(1998) - et al.
Age-related macular degeneration and choroidal neovascularization
Amer J Ophthalmol
(1993) - et al.
Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration
Ophthalmology
(2004) Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes
Am J Ophthalmol
(1994)- et al.
Choroidal neovascularization
Am J Ophthalmol
(2004) - et al.
Choroidal neovascular membranes: reproducibility of angiographic interpretation
Am J Ophthalmol
(2000) - et al.
Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study)
Ophthalmology
(2003) - et al.
Incidence and progression of geographic atrophy: observations from a population-based cohort
Ophthalmology
(2013)
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration two-year results
Ophthalmology
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration
Ophthalmology
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Ophthalmology
Prevalence of age-related macular degeneration in the United States
Arch Ophthalmol
Age-related macular degeneration and blindness due to neovascular maculopathy
Arch Ophthalmol
Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial
Arch Ophthalmol
Treatment of Age-related Macular Degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1
Arch Ophthalmol
Verteporfin in Photodynamic therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2
Am J Ophthalmol
VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration
N Engl J Med
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
Ophthalmology
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
N Engl J Med
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
N Engl J Med
Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model
Retina
Do we need a new classification for choroidal neovascularization in age-related macular degeneration?
Retina
“Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation
Retina
Idiopathic polypoidal choroidal vasculopathy (IPCV)
Retina
Retinal angiomatous proliferation in age-related macular degeneration
Retina
Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation
Retina
Cited by (159)
Practical guidance for imaging biomarkers in exudative age-related macular degeneration
2023, Survey of OphthalmologyNascent Geographic Atrophy as a Predictor of Type 3 Macular Neovascularization Development
2023, Ophthalmology RetinaEvaluation of non-exudative tomographic signs in cases of exudative age-related macular degeneration
2023, Archivos de la Sociedad Espanola de Oftalmologia
Jesse J. Jung received his BA in biology and psychology at Washington University in St. Louis and his MD at Emory University School of Medicine. After completing a transitional year internship at Emory University School of Medicine, he completed his Ophthalmology residency and was Chief Resident during his final year of residency at New York University School of Medicine/Manhattan Eye, Ear, and Throat Hospital. He is currently a second year vitreoretinal fellow at the Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons/Vitreous Retina Macula Consultants of New York/Manhattan Eye, Ear, and Throat Hospital under the mentorship of Drs. Stanley Chang and Lawrence Yannuzzi.
K. Bailey Freund, MD is a Clinical Professor of Ophthalmology at New York University School of Medicine and a senior partner at Vitreous Retina Macula Consultants of New York. Dr Freund is on the Editorial Board of the journal Retina. He has authored over 170 peer-reviewed scientific manuscripts and numerous book chapters. He is a recipient of the Young Investigator Award from the Macula Society.